SML0263
PF-04217903
≥98% (HPLC)
别名:
4-[1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazole-1-ethanol methanesulfonate (1:1)
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H16N8O·CH3SO3H
化学文摘社编号:
分子量:
468.49
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
PF-04217903, ≥98% (HPLC)
InChI
1S/C19H16N8O.CH4O3S/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16;1-5(2,3)4/h1-5,8-10,12,28H,6-7,11H2;1H3,(H,2,3,4)
SMILES string
CS(O)(=O)=O.OCCn1cc(cn1)-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2
InChI key
HBEMHKVWZJTVOC-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: ≥5 mg/mL (warmed)
storage temp.
2-8°C
Quality Level
Gene Information
human ... MET(4233)
Biochem/physiol Actions
PF-04217903 is a c-Met inhibitor.
PF-04217903 is a highly selective, potent inhibitor of the hepatocyte growth factor receptor c-Met. PF-04217903 inhibits endogenous, wild type c-Met in A549 human lung carcinoma cells with an IC50 of 4.8 nM. The compund displays 1000-fold selectivity against a panel of 208 other kinases.
PF-04217903 is an ATP-competitive inhibitor. It elicits antiangiogenic functionality. PF-04217903 inhibits c-Met phosphorylation in xenograft models leading to partial tumor growth suppression.
Application
PF-04217903 has been used as tyrosine-protein kinase Met (C-Met) selective inhibitor in Madin-Darby Canine kidney (MDCK) cells and NT2D1 non-seminoma cells.
Features and Benefits
This compound is featured on the Met page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor
Zou HY, et al.
Molecular Cancer Therapeutics, 11(4), 1036-1047 (2012)
c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells
Leonetti E, et al.
International Journal of Molecular Sciences, 20(2), 320-320 (2019)
c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors
Scheri K, et al.
Testing, 9(61), 31842-31842 (2018)
Erica Leonetti et al.
International journal of molecular sciences, 20(2) (2019-01-17)
: c-MET pathway over-activation is the signature of malignancy acquisition or chemotherapy resistance of many cancers. We recently demonstrated that type II Testicular Germ Cell Tumours (TGCTs) express c-MET receptor. In particular, we elucidated that the non-seminoma lesions express c-MET
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持